# argenx

Source: https://onco.cc/companies/argenx/  
OnCo record `argenx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

argenx is a Belgian antibody company best known for efgartigimod in autoimmune disease; its cancer programme, the anti-CD70 antibody cusatuzumab for acute myeloid leukaemia, was returned by its partner in 2021.

## Summary

argenx, based in Ghent with Dutch and US operations and listed on Euronext and Nasdaq, develops antibodies from its llama-derived SIMPLE Antibody platform. Its lead product efgartigimod is approved for myasthenia gravis and other autoimmune conditions. In cancer it developed cusatuzumab, an anti-CD70 antibody tested with azacitidine in acute myeloid leukaemia, which Janssen licensed in 2018 and handed back in 2021. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: argenx SE; Argenx
- Tags: ctgov-sponsor
- HQ: Ghent
- Type: biotech
- Website: https://www.argenx.com

## Sources

- Official website: https://www.argenx.com
- ClinicalTrials.gov: trials led by argenx: https://clinicaltrials.gov/search?lead=argenx
- Wikipedia: https://en.wikipedia.org/wiki/Argenx

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Cusatuzumab](https://onco.cc/drugs/cusatuzumab/)

---
JSON: https://onco.cc/api/v1/entities/argenx.json